secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001193125-26-144588
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns
-------------------------------------------------------------------------------

- FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.
- Dr. Dominic Smethurst steps down as Chief Medical Officer, effective June 30, 2026.
- Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 (May 29-June 2).
- Company expects to report CRB-701 + Keytruda data in first-line HNSCC in Q4 2026; registrational study for HNSCC to start mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/0001193125-26-144588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/crbp-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-144588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer